Aventis Sues Teva Over ANDA For Generic Actonel

Law360, New York (August 17, 2004, 12:00 AM EDT) -- Aventis has filed a lawsuit against Israeli generic maker Teva Pharmaceuticals over patent rights to osteoporosis drug Actonel.

Aventis, a part of French drugs group Sanofi-Synthelabo, said it filed the lawsuit in response to Teva’s Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic version of the drug. Teva filed its application with the FDA last month, according to Aventis.

Teva argues that its generic version would not infringe on the Actonel patents held in the US by Aventis and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.